Fewer than one in 10 patients eligible to benefit from GLP-1 drugs including Wegovy can access them, warns the World Health Organization as it publishes its initial guidance on the therapies.
With over a billion people worldwide currently obese, it is advocating for broader and more equitable availability to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major obstacles to widespread access to the jabs that can assist patients in reducing considerable body mass, explains the body.
Skinny Jab Scarcity
Despite the present most favorable outlook, the supply of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, per the WHO.
The advice urges governments and firms to increase access, through strategies including voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Jabs Work
These medications imitate a biological compound to slow digestion, curb appetite and boost satiety so users eat less.
Patients usually see weight reduction within a few weeks of beginning the once-weekly jabs.
Research indicates people may regain a significant portion a year later of halting the medication, when their usual appetite resume.
To be above a healthy weight raises your likelihood for experiencing diseases, including type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight impacts individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
